30
Participants
Start Date
September 1, 2022
Primary Completion Date
August 31, 2024
Study Completion Date
February 28, 2025
Nocardia rubra cell wall skeleton
Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
Hepatic arterial infusion chemotherapy
administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
Lenvatinib
12 mg (or 8 mg) once daily (QD) oral dosing
Tislelizumab
200mg intravenously every 3 weeks
RECRUITING
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Collaborators (4)
Chinese Cooperative Group of Liver Cancer
OTHER
Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
OTHER
M&R Pharm
UNKNOWN
Geneplus-Beijing Co. Ltd.
INDUSTRY
Yuce Biotechnology Co., Ltd.
UNKNOWN
Geneis
UNKNOWN
Simcere Pharmaceutical Co., Ltd
OTHER
BeiGene
INDUSTRY
Haplox Biotechnology Co., Ltd.
INDUSTRY
Wan-Guang Zhang
OTHER